Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin in Haplotype Mismatched HSCT
NCT00593554Phase 2Terminated
- Start
- Aug 2007
- Primary completion
- Aug 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palifermin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more (2 arms). Primary endpoint: Treatment-related Mortality Rate at 6 months. Started Aug 2007; status: terminated.
02
Drugs
palifermin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00593554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593554.